Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 2NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 8Thoracic 2Myeloid 2Lymphoid 2Tumor-Agnostic 1Other solid neoplasm 1

Conditions

Myelodysplastic Syndromes 2Thrombocytosis 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Neoplasm, Residual 1Myeloproliferative Disorders 1Leukemia, Neutrophilic, Chronic 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Hypereosinophilic Syndrome 1

Interventions

Cyclophosphamide 229fludarabine phosphate 206fludarabine 163Busulfan 150Mycophenolic Acid 135Tacrolimus 133Whole-Body Irradiation 132Peripheral Blood Stem Cell Transplantation 121Cytarabine 101Azacitidine 100Antilymphocyte Serum 98Melphalan 96Cyclosporine 96Methotrexate 87Imatinib Mesylate 87Filgrastim 85Decitabine 66Granulocyte Colony-Stimulating Factor 60Thiotepa 57venetoclax 53Stem Cell Transplantation 53thymoglobulin 51Radiotherapy 49Cord Blood Stem Cell Transplantation 42nilotinib 40Clofarabine 38Dasatinib 37Methylprednisolone 36ruxolitinib 35Etoposide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × pevonedistat × Myeloid × Clear all
NCT03862157 2026-03-11

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
40 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04712942 2023-08-21

Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat

University of Leipzig

Phase 2 Completed
14 enrolled
Myeloid

Myelodysplastic Syndromes, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡